Key facts
- This page summarizes Gregory D. Perry's Form 4 filing for KALA BIO, Inc. (KALA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Jun 2024, 20:00.
Gregory D. Perry - 11 Jun 2024 Form 4 Insider Report for KALA BIO, Inc. (KALA)
- Reporting relationship
- Director
- Issuer ticker
- KALA
- Reported as of
- 11 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Jun 2024, 20:00:13 UTC
- Prior SEC filing
- 09 May 2024
- Next SEC filing
- 31 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mary Reumuth, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gregory D. Perry filed Form 4 for KALA BIO, Inc. (KALA) on 12 Jun 2024.
Change
- Previous filing in this sequence was filed on 09 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KALA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +1,400
- Change %
- +15%
- Price
- $0.000000
- Shares after
- 10,894
- Date
- 11 Jun 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KALA
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +3,150
- Change %
- Price
- $0.000000
- Shares after
- 3,150
- Date
- 11 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,150
- Exercise price
- $6.18
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024.
Footnote F2
Includes 8,525 unvested RSUs.
Footnote F3
This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024.